A phase-I, open label clinical trial to assess the safety of Tdap vaccine manufactured by Serum Institute of India Pvt. Ltd. in adults

Sharma Hitt; Anil K.; Parekh Sameer; Pujari Pramod; Shewale Sunil; Madhusudhan Rl; Patel Jaya; Eswaraiah Anand; Shaligram Umesh; Gairola Sunil; Rao Harish

首页> 外文期刊>Vaccine >A phase-I, open label clinical trial to assess the safety of Tdap vaccine manufactured by Serum Institute of India Pvt. Ltd. in adults

【24h】

A phase-I, open label clinical trial to assess the safety of Tdap vaccine manufactured by Serum Institute of India Pvt. Ltd. in adults

机译：一阶段I，开放标签临床试验，以评估印度血清研究所制造的TDAP疫苗的安全性PVT。有限公司在成人

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: This first in human study was designed as an open label clinical trial to assess the safety and tolerability of Serum Institute of India Pvt. Ltd. (SIIPL) Tdap vaccine in healthy adult volunteers, aged 1845 years.

机译：背景：这项首次人体试验是一项开放性临床试验，旨在评估印度血清研究所有限公司（SIIPL）Tdap疫苗在1845岁健康成年志愿者中的安全性和耐受性。

著录项

来源
《Vaccine》 |2021年第6期|共4页
作者
Sharma Hitt; Anil K.; Parekh Sameer; Pujari Pramod; Shewale Sunil; Madhusudhan Rl; Patel Jaya; Eswaraiah Anand; Shaligram Umesh; Gairola Sunil; Rao Harish;
展开▼
作者单位

Serum Inst India Pvt Ltd Pune 411028 Maharashtra India;

Syngene Int Ltd Bangalore Karnataka India;

Serum Inst India Pvt Ltd Pune 411028 Maharashtra India;

Serum Inst India Pvt Ltd Pune 411028 Maharashtra India;

Serum Inst India Pvt Ltd Pune 411028 Maharashtra India;

Syngene Int Ltd Bangalore Karnataka India;

Syngene Int Ltd Bangalore Karnataka India;

Syngene Int Ltd Bangalore Karnataka India;

Serum Inst India Pvt Ltd Pune 411028 Maharashtra India;

Serum Inst India Pvt Ltd Pune 411028 Maharashtra India;

Serum Inst India Pvt Ltd Pune 411028 Maharashtra India;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医学免疫学;
关键词
Tdap; Safety; Adult; Phase I; Vaccine;

机译：Tdap;安全成人第一阶段;疫苗;

相似文献

外文文献
中文文献

1. Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults:randomized,double-blind,and placebo-controlled phase 1 and phase 2 clinical trials [J] . Hong-Xing Pan, Jing-Xin Li, Dan-Dan Zhu, 中华医学杂志（英文版） . 2021,第011期
2. Immunogenicity and safety of a recombinant fusion protein vaccine(V-01)against coronavirus disease 2019 in healthy adults:a randomized,double-blind,placebo-controlled,phase Ⅱ trial [J] . Ya-Jun Shu, Jian Zhou, Yuan-Qin Min, 中华医学杂志（英文版） . 2021,第016期
3. Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip) to adults aged 鈮?0 Years: an open-label, randomised trial. [J] . Zimmermann U., Gavazzi G., Richard P., Vaccine . 2013,第11期

机译：≥0岁的成年人同时接种非白喉，破伤风，无细胞百日咳和脊髓灰质炎灭活疫苗（Tdap-IPV; Repevax）的加强剂量的免疫原性和安全性，随机试验。
4. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults. [J] . Thierry-Carstensen B, Jordan K, Uhlving HH, Vaccine . 2012,第37期

机译：与破伤风和白喉疫苗相比，破伤风，白喉和单组分无细胞百日咳（TdaP）疫苗的安全性和免疫原性的随机，双盲，非劣效性临床试验，作为健康成年人的加强疫苗接种。
5. Immunogenicity and safety results from a randomized multicenter trial comparing a Tdap-IPV vaccine (REPEVAX1 and a tetanus monovalent vaccine in healthy adults New considerations for the management of patients with tetanus-prone injuries [J] . Henri Laurichesse, Ulrich Zimmermann, Florence Galtier, Human vaccines . 2012,第12期

机译：在健康成年人中比较Tdap-IPV疫苗（REPEVAX1和破伤风单价疫苗）的随机多中心试验的免疫原性和安全性结果管理易于破伤风的患者的新注意事项
6. Efficacy and safety of novel collagen conduits filled with collagen filaments to treat patients with peripheral nerve injury: A multicenter, controlled, open-label clinical trial [D] . Saeki Masaomi, 佐伯将臣 2019

机译：充满胶原细丝的新型胶原蛋白导管治疗周围神经损伤患者的疗效和安全性：一项多中心，对照，开放标签的临床试验
7. Immunogenicity and Safety of a Tetravalent Recombinant Subunit Dengue Vaccine in Adults Previously Vaccinated with a Live Attenuated Tetravalent Dengue Vaccine: Results of a Phase-I Randomized Clinical Trial [O] . Anna P. Durbin, Kristen K. Pierce, Beth D. Kirkpatrick, 2020

机译：用活化的四价疫苗预接种疫苗的成年人中的四价重组亚基登革热疫苗的免疫原性和安全性：相-I随机临床试验的结果
8. Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose [O] . Scott A Halperin, Catherine Donovan, Gary S Marshall, 2018

机译：在以前剂量后10年后，随机对照试验在成人后的Tetanus-Diphtheria-yenellular-evellularysis疫苗（TDAP）的安全性和免疫原性
9. Guidance for Industry. Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials [R] . 2007

机译：工业指南。参加预防性疫苗临床试验的健康成人和青少年志愿者的毒性分级量表

A phase-I, open label clinical trial to assess the safety of Tdap vaccine manufactured by Serum Institute of India Pvt. Ltd. in adults

摘要

著录项

相似文献

相关主题

期刊订阅